RG
ADAP

Redmile Group’s Adaptimmune Therapeutics ADAP Stock Holding History

Redmile Group’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-715,607
Closed -$385K – 58
2024
Q4 		$385K Hold
715,607
– – 0.03% 60
2024
Q3 		$680K Hold
715,607
– – 0.04% 62
2024
Q2 		$698K Hold
715,607
– – 0.04% 61
2024
Q1 		$1.13M Hold
715,607
– – 0.04% 74
2023
Q4 		$567K Hold
715,607
– – 0.02% 68
2023
Q3 		$558K Hold
715,607
– – 0.03% 66
2023
Q2 		$662K Buy
+715,607
New +$853K 0.03% 71

Other funds holding ADAP

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Redmile Group's ADAP Position: Q1 2025 in Review

Redmile Group sold out of Adaptimmune Therapeutics (ADAP) in Q1 2025, closing a stake of 715,607 shares — an estimated $385K sold.

Redmile Group first reported a position in ADAP in Q2 2023 and held it in 7 quarters. The position peaked at $1.13M in Q1 2024. 67 funds tracked by Wall St. Rank hold ADAP as of Q1 2025.

  • Redmile Group reported no remaining Adaptimmune Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Redmile Group sold 715,607 Adaptimmune Therapeutics shares in Q1 2025, an estimated $385K.
  • Redmile Group first reported a position in Adaptimmune Therapeutics in Q2 2023 and held it in 7 quarters.
  • Redmile Group's Adaptimmune Therapeutics position peaked at $1.13M in Q1 2024.
  • 67 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2025.

Based on Redmile Group's 13F filing for Q1 2025, filed 15 May 2025.